James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

5 Stocks to Buy for December

Software stocks are strongly positioned for oversized growth this month. Here are the best stocks to buy from the group.

Why Amazon.com, Inc. (AMZN) Stock Holders Should Fear Amazon Go

Amazon (AMZN) has developed numerous concepts that have driven AMZN stock higher. Amazon Go will not be one of those things.

Why Chipotle Mexican Grill, Inc. (CMG), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Rent-A-Center Inc (RCII) Are 3 of Today’s Worst Stocks

Chipotle (CMG), Rent-A-Center (RCII) and Teva Pharmaceutical (TEVA) were all overwhelmed by bad news today.

GW Pharmaceuticals PLC- ADR (GWPH) Stock Is Just Getting Started

GW Pharmaceuticals took a big leap forward today, but these next few years are when GWPH stock will really start to shine.

Why Twitter Inc (TWTR) Stock Believers Need to Act Now

Buying TWTR stock is like catching a falling knife, but worth the danger if you really believe Twitter has a viable future.